Media coverage about Sinovac Biotech (NASDAQ:SVA) has been trending somewhat negative this week, according to Accern. Accern rates the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Sinovac Biotech earned a coverage optimism score of -0.02 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.8195673514175 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Several analysts recently commented on the company. BidaskClub upgraded Sinovac Biotech from a “hold” rating to a “buy” rating in a research report on Tuesday, March 20th. ValuEngine upgraded Sinovac Biotech from a “hold” rating to a “buy” rating in a research report on Saturday, June 2nd.
SVA traded down $0.13 during trading hours on Tuesday, hitting $7.65. The company’s stock had a trading volume of 100 shares, compared to its average volume of 37,629. Sinovac Biotech has a fifty-two week low of $6.50 and a fifty-two week high of $8.75. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.99 and a current ratio of 2.20.
Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against enterovirus71 (EV710), hepatitis A and B, seasonal influenza, H5N1 pandemic influenza, H1N1 influenza, and mumps, as well as hand, foot, and mouth diseases.
Further Reading: What does EPS mean?
Receive News & Ratings for Sinovac Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech and related companies with MarketBeat.com's FREE daily email newsletter.